Journal of Global Infectious DiseasesOfficial Publishing of INDUSEM and OPUS 12 Foundation, Inc. Users online:186  
Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size     
Home About us Editors Ahead of Print Current Issue Archives Search Instructions Subscribe Advertise Login 

   Table of Contents     
Year : 2020  |  Volume : 12  |  Issue : 4  |  Page : 165-166
State of the globe: “Hansen's disease – Down but not out in the SARS-CoV-2 era”

1 Department of Microbiology, Indira Gandhi Medical College, Shimla, Himachal Pradesh, India
2 Department of Medicine, Indira Gandhi Medical College, Shimla, Himachal Pradesh, India

Click here for correspondence address and email

Date of Submission20-Nov-2020
Date of Acceptance21-Nov-2020
Date of Web Publication30-Nov-2020

How to cite this article:
Thakur S, Chauhan V. State of the globe: “Hansen's disease – Down but not out in the SARS-CoV-2 era”. J Global Infect Dis 2020;12:165-6

How to cite this URL:
Thakur S, Chauhan V. State of the globe: “Hansen's disease – Down but not out in the SARS-CoV-2 era”. J Global Infect Dis [serial online] 2020 [cited 2022 Aug 8];12:165-6. Available from:

Hansen's disease (leprosy) was infamously known as “The Death Before the Death” because patients with leprosy had to deal not only with the physical and facial deformities but also with the ostracism from their own families and society.[1] People were fearful of the contagious nature of the disease and therefore leprosy patients were declared outcast and forced to live outside their main habitations in the so-called Lazar houses by religious orders.[1]

In 1897, leading experts from around the world gathered in Berlin for the first Leprosy congress, and the only thing they all agreed upon was that leprosy was incurable.[2] Leprosy patients suffered from destruction of facial cartilaginous tissues of nose, ears with loss of eyebrows, and formation of nodular lesions over the face, typically called “facies leprosa.”[2] Leprosy patients also developed nerve lesions, resulting in numbness of the extremities, painless ulcerations of the hands and feet progressing to resorption, and destruction of digits.[3] These typical manifestations of leprosy instilled fear in the family members and the society because there was no known treatment, and it was considered contagious. Leprosy became associated with a significant social stigma.[1]

The disease is thought to have originated in India with oldest clear descriptions of leprosy from India between 600 BC and 1500 BC.[2] The disease is thought to have spread to the Mediterranean region with the returning soldiers of the Alexander the Great after their quest in India between 327 and 326 BC.[2] The slave trade then took it further to Africa and rest of the world over time.[2]

Dr. Hansen was the first to discover rod-shaped bacilli in a patient's nasal biopsy specimen under a microscope and proposed these bacilli as the causative agent of leprosy, called Mycobacterium leprae.[1] The disease has been named after him as the Hansen's disease.[1]

We have come a long way since the dark ages when leprosy patients were left to die in Lazar houses. With the discovery of drugs such as dapsone, clofazimine, and rifampicin and the demonstration of their ability to cure all forms of Hansen's disease, the world is now inching toward its elimination.[4] In 2015, 211,973 new cases of Hansen's disease were reported globally.[4] India alone contributed 60% of the global load of new cases of leprosy, followed by Brazil (13%) and Indonesia (8%).[4] Barring these three nations, there was no other country that reported over 10,000 annual cases of Hansen's disease in 2015.[4]

Research on leprosy has shown that among contagious agents, Hansen's disease is the least readily transmitted infection. Prolonged close contact with a person with untreated disease is required for its transmission, while 95% of the world's population is naturally immune to this disease.[3] Treatment of leprosy is given in the form of a combination chemotherapy to avoid the development of resistance to the available drugs, and it needs to be taken for 1–2 years depending on its paucibacillary or multibacillary nature.[3] Free drugs for leprosy are provided by the World Health Organization (WHO) to all the countries around the world.[4]

The vision of global leprosy strategy includes four main points, that is, zero disease, zero transmission of leprosy, zero disability due to leprosy, and zero stigma and discrimination.[4] Leprosy is one of the neglected tropical diseases, and research, training, and dissemination of knowledge of leprosy is lacking among practitioners in tropical countries. To eliminate leprosy, it is important that the new cases be detected at an early stage of development of disease so that treatment can be started before the development of any deformities.[4] This will also ensure that these patients do not spread the infection to the people surrounding them. Patients with leprosy become noncontagious after taking few doses of combination chemotherapy.[4]

India reported 137,685 new cases of leprosy in 2007, and, in 2016, the number remained almost the same at 135,485.[5] The Indian government is conducting the Leprosy Case Detection Campaign in the fifty highly endemic districts of India with the help of accredited social health activists.[5] The role of medical and nursing schools cannot be undermined for this disease because if they stop training their graduates in the diagnosis of leprosy, the future generations of physicians and nurses will miss many more cases, resulting in the resurgence of leprosy as has been noted in many states of India.[5] With the decline in the number of cases of Hansen's disease, the physicians in the USA have been found to easily miss the diagnosis.[3] Physicians worldwide need training in the common early manifestations of the disease on the skin, face, nerves, and mucosa. The missed diagnosis allows the bacillus to grow and spread in the society till the advanced form of disease brings it to the notice of everyone. The WHO is making efforts to educate physicians using smart technologies. The WHO recently launched a mobile-based app to help physicians diagnose leprosy with ease in their clinics.[6]

The ongoing SARS-CoV-2 pandemic has disrupted the health-care services worldwide that has severely affected the community programs for tuberculosis and leprosy in high-burden countries. On the brighter side, the pandemic has increased the adoption of internet-based telemedicine technologies by the physicians.[7] Tele-dermatology can help increase the outreach of expert dermatologists to the remote areas in need of exert opinions for diagnosing leprosy.

India remains the hub of leprosy in the world, and the disruptions brought about by the pandemic may lead to resurgence of this disease in some pockets of the world. Atram et al.[8] have given a clinico-histopathological correlation of Hansen's disease in a rural tertiary care hospital in central India in the current issue of this journal, reminding us of a historically important disease that is down but not yet out.

   References Top

Bennett BH, Parker DL, Robson M. Leprosy: Steps along the journey of eradication. Public Health Rep 2008;123:198-205.  Back to cited text no. 1
Browne SG. How old is leprosy? Br Med J 1970;3:640-1.  Back to cited text no. 2
Hansen's Disease (Leprosy): Centers for Disease Control and Prevention; February 10, 2017. Available from: [Last accessed on 2020 Nov 19].  Back to cited text no. 3
Epidemiology: Leprosy Elimination. World Health Organization; 2020. Available from: [Last accessed on 2020 Nov 19].  Back to cited text no. 4
Rao PN, Suneetha S. Current situation of leprosy in India and its future implications. Indian Dermatol Online J 2018;9:83-9.  Back to cited text no. 5
[PUBMED]  [Full text]  
Neglected Tropical Diseases of the Skin: WHO Launches Mobile Application to Facilitate Diagnosis. WHO; 2020. Available from: [Last accessed on 2020 Nov 19].  Back to cited text no. 6
Chauhan V, Galwankar S, Arquilla B, Garg M, Somma SD, El-Menyar A, et al. Novel coronavirus (COVID-19): Leveraging telemedicine to optimize care while minimizing exposures and viral transmission. J Emerg Trauma Shock 2020;13:20-4.  Back to cited text no. 7
  [Full text]  
Atram MA, Ghongade PV, Gangane NM. A clinicohistopathological correlation of Hansen's disease in a rural tertiary care hospital of Central India. J Global Infect Dis 2020;12:191-6.  Back to cited text no. 8
  [Full text]  

Correspondence Address:
Dr. Vivek Chauhan
Indira Gandhi Medical College, Shimla, Himachal Pradesh
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jgid.jgid_396_20

Rights and Permissions

This article has been cited by
1 Hansen's disease and COVID -19 co-infection in Brazil
Taynah Alves Rocha Repsold, Simon M. Collin, Raquel Carvalho Bouth, Selma Regina Penha Silva Cerqueira, Marisa Simon Brezinscki, Rebeca Ruppert Galarda Baptista Peixoto, Andrea Maia Fernandes de Araújo Fonseca, Marlene Leandro dos Santos Peixoto, Seyna Rabelo Mendes, Ciro Martins Gomes, Claudio Guedes Salgado, Patrícia D. Deps
International Journal of Dermatology. 2022;
[Pubmed] | [DOI]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Email Alert *
    Add to My List *
* Registration required (free)  


 Article Access Statistics
    PDF Downloaded109    
    Comments [Add]    
    Cited by others 1    

Recommend this journal

Sitemap | What's New | Feedback | Copyright and Disclaimer | Privacy Notice | Contact Us
© 2008 Journal of Global Infectious Diseases | Published by Wolters Kluwer - Medknow
Online since 10th December, 2008